Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Advanced Cancer
91%
Neoplasm
88%
Clinical Trial
88%
Malignant Neoplasm
82%
Diseases
81%
Bevacizumab
41%
Adverse Event
41%
Phase I Trials
37%
Overall Survival
37%
Progression Free Survival
35%
Paclitaxel
34%
Ovary Cancer
27%
Maximum Tolerated Dose
26%
Pharmacokinetic
26%
Antitumor Activity
24%
Chemotherapy
22%
Epidermal Growth Factor Receptor
21%
Carboplatin
21%
Oxaliplatin
19%
Colorectal Carcinoma
19%
Vasculotropin
18%
Breast Cancer
17%
Thrombocytopenia
16%
Mammalian Target of Rapamycin Inhibitor
15%
Temsirolimus
15%
Cetuximab
14%
Immunotherapy
14%
Combination Therapy
14%
Selinexor
13%
Melanoma
13%
Metastasis
13%
Adavosertib
12%
Erlotinib
12%
Non Small Cell Lung Cancer
12%
Diarrhea
12%
Ovary Carcinoma
12%
Phosphotransferase Inhibitor
11%
Rash
11%
Liver Metastasis
11%
Connective Tissue Cancer
11%
Uterine Cervix Cancer
11%
Tolerability
11%
Pazopanib
11%
Lenalidomide
11%
Sodium Valproate
11%
Fluorouracil
10%
Female Genital Tract Cancer
10%
Prevalence
9%
Biological Marker
9%
Keyphrases
Patients with Advanced Cancer
74%
Stable Disease
57%
Advanced Solid Tumors
52%
Phase I Study
49%
Partial Response
45%
Phase I Clinical Trial
43%
Bevacizumab
41%
Phase I Trial
39%
MD Anderson Cancer Center
34%
Dose-limiting Toxicity
27%
PIK3CA mutation
25%
Paclitaxel
24%
Confidence Interval
22%
Early Phase Clinical Trials
22%
Maximum Tolerated Dose
22%
Targeted Therapy
22%
Overall Survival
20%
Antitumor Activity
20%
Advanced Cancer
19%
MTOR Inhibitor
19%
Tumor
18%
Non-small Cell Lung Cancer (NSCLC)
18%
Mammalian Target of Rapamycin (mTOR)
18%
Ovarian Cancer
16%
Tumor Subtype
16%
Progression-free Survival
16%
Cetuximab
16%
Hepatic Arterial Infusion
16%
Clinical Trials
16%
Carboplatin
15%
Median Progression-free Survival
15%
Chemotherapy
15%
Adverse Events
15%
Temsirolimus
15%
Solid Tumors
15%
KRAS mutation
15%
Dose Level
14%
Dose Escalation
14%
Dose-escalation Study
13%
Advanced Malignancies
13%
TP53 mutation
13%
PIK3CA
13%
Clinical Outcomes
13%
Pazopanib
13%
Selinexor
13%
Center Experience
13%
VEGF Inhibitors
13%
Clinical Benefit
12%
Sarcoma
12%
Median Overall Survival
12%
Medicine and Dentistry
Clinical Trial
71%
Neoplasm
64%
Advanced Cancer
60%
Malignant Neoplasm
50%
Cancer
50%
Diseases
41%
Overall Survival
30%
Targeted Therapy
30%
Progression Free Survival
29%
Solid Malignant Neoplasm
23%
Ovarian Cancer
23%
Immunotherapy
18%
Phase I Trials
17%
Metastatic Carcinoma
15%
Mammalian Target of Rapamycin Inhibitor
13%
Krukenberg Tumor
13%
Epidermal Growth Factor Receptor
13%
Adverse Event
13%
Colorectal Carcinoma
12%
Connective Tissue Cancer
12%
Bevacizumab
12%
Mammalian Target of Rapamycin
11%
Antineoplastic Activity
11%
Pembrolizumab
11%
Next Generation Sequencing
11%
PI3K/AKT/mTOR Pathway
10%
Carboplatin
10%
Hazard Ratio
9%
Systemic Therapy
9%
Cancer Therapy
9%
Personalized Medicine
9%
Melanoma
9%
Cell-Free DNA
9%
Oxaliplatin
9%
Cancer Cell
8%
Paclitaxel
8%
Hepatic Arterial Infusion
8%
Prevalence
8%
Breast Cancer
8%
Non Small Cell Lung Cancer
8%
Adavosertib
8%
Vasculotropin
8%
Multivariate Analysis
8%
Cervical Cancer
7%
Oncology
7%
Lung Cancer
7%
Combination Therapy
7%
Vorinostat
7%
Programmed Cell Death
6%
Rapamycin
6%